Broad susceptibility of Candida auris strains to 8-hydroxyquinolines and mechanisms of resistance.

ABSTRACT: The fungal pathogen Candida auris represents a severe threat to hospitalized patients. Its resistance to multiple classes of antifungal drugs and ability to spread and resist decontamination in healthcare settings make it especially dangerous. We screened 1,990 clinically approved and late-stage investigational compounds for the potential to be repurposed as antifungal drugs targeting C. auris and narrowed our focus to five Food and Drug Administration (FDA)-approved compounds with inhibitory concentrations under 10 µM for C. auris and significantly lower toxicity to three human cell lines. These compounds, some of which had been previously identified in independent screens, include three dihalogenated 8-hydroxyquinolines: broxyquinoline, chloroxine, and clioquinol. A

SUBMITTER: Lohse MB 

PROVIDER: S-EPMC10470496 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature